The capabilities are genuinely differentiated: a) ADC: Filed 3 payload DMFs in FY26, completed first cGMP bioconjugation campaign at NJ Bio (US facility), expanding with $10 Mn capex for Phase 2/validation readiness, traction in exatecan-linked platforms b) Oligonucleotide : cGMP building block facility under validation through the Sapala platform, follow-on purchase orders received c) Small Molecule CDMO: 140+ active projects, 70%+ from commercial products, 90%+ reload conversion rate d) Phase 3 pipeline: 10 programs including 1 under priority review and 1 awaiting clinical data readout However, FY26 was operationally challenging
President Donald Trump has also pushed for lower drug prices, and a November deal with the administration slashed GLP-1 prices in the country
Secondary carnitine deficiency due to acquired conditions: hemodialysis, taking anticonvulsants: sodium valproate, pivampicillin therapy
IN 1 SERVING: 1000 mg L-Carnintine Tartrate Security policy Delivery policy Return policy L-Carnitine 1000 mg contains 1000 mg of a highly efficient and pure L-Carnitine Tartrate
Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP318
Proliferation of peroxisomes can account for up to 20% increase in hepatocytes volume with a twenty- to thirty-fold increase in fatty acid -oxidation
